Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany

NEXT STORY
Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
PREV STORY
Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Oncology Venture A/S establish a flexible loan facility of up to SEK 40 million

Oncology Venture A/S ("Oncology Venture", formerly Medical Prognosis Institute A/S) hereby announces that the ...

author_avatar
NASDAQ Market News

BeiGene to Present at the Cowen and Company 37th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical ...

author_avatar
NASDAQ Market News

Shire plc : Directorate change

Directorate Change Dublin, Ireland - January 19, 2018 - Shire plc (LSE: SHP, NASDAQ: ...

author_avatar
NASDAQ Market News